Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.90 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.77 |
| ▸ | APLNR | P35414 | 1/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.77 |
| ▸ | GLP1R | P43220 | 1/20 | 0.77 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.77 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.77 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727261 | 0.96 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL19759864 | 0.95 | GNRHR (0.90) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL29396002 | 0.94 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL29365599 | 0.94 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL4677617 | 0.94 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL19549512 | 0.94 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL1642523 | 0.94 | GNRHR (1.00) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL1641993 | 0.93 | GNRHR (0.99) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| Elagolix SCHEMBL1641996 | 0.93 | GNRHR (0.99) | GNRHRCYP3A4ADRB2APLNROPRK1 | |
| SCHEMBL23958943 | 0.90 | GNRHR (0.89) | GNRHRCYP3A4ADRB2APLNROPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117969-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADENOMYOSIS AND RECTOVAGINAL ENDOMETRIOSIS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117969-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADENOMYOSIS AND RECTOVAGINAL ENDOMETRIOSIS | GNRHR, PGR, NR5A1 | GNRHR 1/4885CYP3A4 4337/4885ADRB2 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.